Figure 5From: In vivo therapeutic efficacy and pharmacokinetics of colistin sulfate in an experimental model of enterotoxigenic Escherichia coli infection in weaned pigs Evolution of plasma CS concentrations over time in pigs challenged with an ETEC: F4 strain and receiving colistin sulfate (CS) orally (mean ± standard deviation [SD]). Colistin sulfate concentrations were obtained by HPLC–MS/MS after 0.5, 12, 24 and 48 h of CS treatment discontinuation at a therapy regimen of 100 000 IU/kg (trial 1) or 50 000 IU/kg (trial 2). In trial 1, at 0.5, 12 and 24 h, CS concentrations were statistically higher in the challenged treated group compared to the unchallenged treated group with p < 0.001, p < 0.0001 and p < 0.001 respectively. In trial 2, at 0.5 and 12 h, CS concentration was statistically higher in the challenged treated group compared to the unchallenged treated group with p < 0.001 and p = 0.04 respectively (n = 8 per group).Back to article page